T-knife

T-knife is a preclinical-stage biopharmaceutical company developing tumor-specific T-cell receptor (TCR) therapies. Founded in 2018 by Thomas Blankenstein, Elisa Kieback, and Holger Specht, T-knife is a spin-off from the Max-Delbruck Center for Molecular Medicine and is supported by Charité University Hospital in Berlin, Germany.